Palvella Therapeutics (NASDAQ:PVLA) Stock Price Expected to Rise, Oppenheimer Analyst Says

Palvella Therapeutics (NASDAQ:PVLA) had its target price increased by research analysts at Oppenheimer from $210.00 to $232.00 in a report released on Friday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer‘s target price suggests a potential upside of 32.40% from the company’s current price.

PVLA has been the topic of a number of other reports. Raymond James Financial set a $226.00 target price on shares of Palvella Therapeutics in a research report on Friday, October 16th. William Blair began coverage on shares of Palvella Therapeutics in a research report on Friday, October 16th. They issued an “outperform” rating for the company. Truist Financial set a $207.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. Chardan Capital reaffirmed a “buy” rating and set a $240.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, October 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Palvella Therapeutics has an average rating of “Moderate Buy” and an average target price of $213.00.

Palvella Therapeutics Trading Up 11.7%

PVLA stock traded up $18.38 during trading on Friday, hitting $175.22. 116,088 shares of the company’s stock were exchanged, compared to its average volume of 260,139. The business has a 50-day moving average price of $142.03 and a two-hundred day moving average price of $127.73. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of -36.36 and a beta of -0.21. Palvella Therapeutics has a 52-week low of $72.22 and a 52-week high of $174.60.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Thursday, November 5th. The company reported ($1.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.78) by $0.08. On average, equities research analysts anticipate that Palvella Therapeutics will post -6.39 earnings per share for the current fiscal year.

Insider Buying and Selling at Palvella Therapeutics

In related news, Director Christopher Kiritsy sold 313 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total transaction of $49,141.00. Following the completion of the sale, the director directly owned 250 shares of the company’s stock, valued at $39,250. This trade represents a 55.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director George Jenkins sold 7,174 shares of the business’s stock in a transaction dated Tuesday, October 13th. The stock was sold at an average price of $130.36, for a total transaction of $935,202.64. Following the transaction, the director owned 139,790 shares in the company, valued at approximately $18,223,024.40. This trade represents a 4.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 61,056 shares of company stock valued at $8,756,946 in the last ninety days. Insiders own 17.20% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in PVLA. KBC Group NV purchased a new stake in shares of Palvella Therapeutics in the first quarter valued at about $28,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Palvella Therapeutics during the second quarter valued at $35,000. Sterling Capital Management LLC boosted its stake in shares of Palvella Therapeutics by 907.7% during the third quarter. Sterling Capital Management LLC now owns 393 shares of the company’s stock valued at $54,000 after acquiring an additional 354 shares during the last quarter. Archer Investment Corp acquired a new stake in shares of Palvella Therapeutics during the second quarter valued at $69,000. Finally, Quantbot Technologies LP purchased a new stake in Palvella Therapeutics during the 2nd quarter worth about $71,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.

The company’s development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.